Cochrane · systematic review · CD007813
Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults
Castells, X, Blanco‐Silvente, L, Cunill, R · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
11
current version
GRADE rated
7
No studies
4
Included studies
NR
No studies 4 · 36.4%Ungraded 0 · 0%Very low 2 · 18.2%Low 5 · 45.5%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyAmphetamines versus placebo for attention deficit hyperactivity disorder (ADHD) in adults
Population: adult patients with attention deficit hyperactivity disorder (ADHD)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Dexamphetamine Amphetamines vs placebo | no estimate extracted | NR | No studies |
ADHD symptom severity: clinician rated Amphetamines vs placebo | no estimate extracted | 1 study · 49 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
ADHD symptom severity: patient rated Amphetamines vs placebo | no estimate extracted | 2 studies · 35 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Lisdexamfetamine Amphetamines vs placebo | no estimate extracted | NR | No studies |
ADHD symptom severity: clinician rated Amphetamines vs placebo | no estimate extracted | 7 studies · 896 participants | Low Downgraded: risk of bias, inconsistency, publication bias |
ADHD symptom severity: patient rated Amphetamines vs placebo | no estimate extracted | 3 studies · 67 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Mixed amphetamine salts Amphetamines vs placebo | no estimate extracted | NR | No studies |
ADHD symptom severity: clinician rated Amphetamines vs placebo | no estimate extracted | 5 studies · 1083 participants | Low Downgraded: risk of bias, publication bias |
ADHD symptom severity: patient rated Amphetamines vs placebo | no estimate extracted | 1 study · 18 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
All amphetamines Amphetamines vs placebo | no estimate extracted | NR | No studies |
Retention in treatment Amphetamines vs placebo | RR 1.06 [0.99, 1.13] | 17 studies · 2323 participants | Low Downgraded: risk of bias, inconsistency |
Amfetamine derivatives compared to Placebo for adult ADHD for Attention Deficit Hyperactivity Disorder (ADHD) in adults
Population: Adults with Attention Deficit Hyperactivity Disorder (ADHD)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
ADHD symptom severity ‐ Dexamphetamine Amfetamine derivatives vs Placebo | no estimate extracted | 3 studies · 84 participants | Very low Downgraded: risk of bias, inconsistency, publication bias |
ADHD symptom severity ‐ Lisdexamphetamine Amfetamine derivatives vs Placebo | no estimate extracted | 1 study · 414 participants | Low Downgraded: risk of bias, publication bias |
ADHD symptom severity ‐ Mixed amphetamine salts Amfetamine derivatives vs Placebo | no estimate extracted | 2 studies · 512 participants | Low |
ADHD symptom severity ‐ Any amphetamine derivative Amfetamine derivatives vs Placebo | no estimate extracted | 6 studies · 1045 participants | Low |
Retention in treatment ‐ Dexamphetamine Amfetamine derivatives vs Placebo | RR 0.96 [0.8, 1.14] | 2 studies · 93 participants | Low Downgraded: risk of bias, publication bias |
Retention in treatment ‐ Lisdexamphetamine Amfetamine derivatives vs Placebo | RR 0.99 [0.88, 1.11] | 1 study · 420 participants | Low Downgraded: risk of bias, publication bias |
Retention in treatment ‐ Mixed amphetamine salts Amfetamine derivatives vs Placebo | RR 1.19 [1.06, 1.35] | 3 studies · 559 participants | Low Downgraded: risk of bias, publication bias |
Retention in treatment ‐ Any amphetamine derivative Amfetamine derivatives vs Placebo | RR 1.06 [0.96, 1.18] | 6 studies · 1072 participants | Very low Downgraded: risk of bias, inconsistency, publication bias |